查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863478

器官移植诊断市场按检测类型、器官类型、技术、应用和最终用户划分－2025-2032年全球预测

Organ Transplant Diagnostics Market by Test Type, Organ Type, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，器官移植诊断市场将成长至 80.8 亿美元，复合年增长率为 7.69%。

关键市场统计数据
基准年 2024 44.6亿美元
预计年份：2025年 48亿美元
预测年份 2032 80.8亿美元
复合年增长率 (%) 7.69%

器官移植诊断的策略概述：重点关注当前临床重点和影响其应用的营运趋势

器官移植诊断处于精准医疗、实验室创新和复杂临床流程的交会点，快速且准确的检测决定着移植结果和病患的生存率。诊断方法涵盖基因谱分析、组织相容性评估、分子监测和血清学检测，每种方法都具有独特的临床价值，从捐赠者选择到长期移植后监测均发挥作用。近年来，临床环境对高解析度分子数据和操作简便性的需求日益增长，以满足紧迫的临床时间要求，这迫使供应商和实验室重新评估平台互通性和结果报告策略。

因此，临床和商业性相关人员必须了解检测途径如何与移植计画的物流、免疫抑制策略和感染监测通讯协定整合。结合临床背景解读检测结果，有助于降低免疫风险、指南免疫调节并改善器官分配决策。随着该领域的不断发展，决策者需要在新型高解析度检测和分析技术与实验室认证、报销机制和供应连续性等实际限制因素之间取得平衡。鑑于这些优先事项，本执行摘要总结了影响诊断技术应用的关键转折点，指出了基于细分市场的机会，并为希望将证据转化为营运优势的领导者提出了切实可行的建议。

技术创新、监管重点和临床工作流程重组正在推动移植诊断关键性再形成。

移植诊断领域正经历变革性的转变，这主要得益于技术进步、监管调整以及临床实践模式的演变。次世代定序技术和高灵敏度分子检测显着提高了诊断准确性，实现了更精准的供受者匹配，并能更早发现排斥反应和感染疾病。同时，检测自动化和数位化报告技术的进步减少了人工操作，并加快了临床决策週期，迫使移植团队重新设计工作流程，以确保及时获得检测结果。

同时，支付方和医疗系统越来越重视基于价值的医疗结果，要求诊断试剂供应商透过真实世界数据和成本效益分析来证明其临床效用。监管机构也日益关注检测标准化和互通性，鼓励供应商采用统一的通讯协定并参与外部品质评估。此外，供应链韧性已成为一项策略重点，相关人员强调试剂来源多元化和检验的紧急时应对计画。这些变化共同创造了一种市场环境，除了技术差异化之外，还需要证据支持、供应稳定和营运整合，才能在移植中心和诊断实验室中获得广泛应用。

预测美国关税政策变化对诊断供应链、筹资策略和临床准入的累积影响

改变关税结构的政策措施会对诊断平台和耗材的可用性、成本基础和筹资策略产生重大影响，尤其会对依赖专业检测和国际供应链的移植项目造成显着衝击。关税上涨时，实验室和医院通常会寻找替代供应商、透过集中采购整合采购，并加快相容试剂和设备的现场检验。同时，关税政策的降低或澄清通常能够恢復可预测的采购前置作业时间，并支持因成本不确定性而推迟的平台升级投资。

事实上，对移植诊断产业的累积影响包括库存管理实践的变更、重新评估供应商合约以纳入关税相关条款，以及重新重视区域製造伙伴关係以保护关键供应链。重点，诊断决策者也必须考虑间接影响。关税带来的成本压力可能会延迟新检测方法的检验，压缩专业实验室的利润率，并影响其继续在国内采购还是从国外采购的决策。为了减轻营运中断的影响，临床实验室和医院系统应提高供应链的透明度，重新谈判包含服务水准保护条款的条款，并优先考虑建立多元化的供应商生态系统，以降低单一供应商遭受关税衝击的风险。

详细的分割分析将诊断方式、器官特异性工作流程、平台技术、临床应用和最终用户能力连结起来

细緻的细分方法揭示了不同检测类型、器官特异性适应症、平台技术、应用领域和终端用户环境之间存在的显着需求驱动因素和营运重点。检测类型区分了基因检测（包括DNA定序和SNP基因型鉴定）与组织相容性检测流程（例如交叉配对试验和HLA型检测），并进一步区分了分子方法（例如次世代定序和PCR）与血清学技术（包括ELISA和流式细胞技术）。这些诊断方法直接满足器官特异性需求，心臟、肾臟、肝臟、肺臟和胰臟移植项目对敏感度、通量和周转时间等特性各有重点。肾臟和肝臟移植计画也因脑死捐赠者与活体捐赠者流程的不同而存在差异，这会影响移植前配对和移植后后续观察的需求。

从技术角度来看，ELISA 和流式细胞技术仍然是许多实验室的基础技术，而微阵列平台、标靶或全基因组定序以及先进的 PCR 技术则支援更深入的免疫遗传学分析。从应用角度来看，移植前配型活动（例如交叉检测和 HLA 匹配）需要快速、高度特异性的结果来确定器官分配。同时，移植后监测着重于感染筛检和排斥反应监测，需要连续采样和可靠的定量分析。最终用户环境涵盖诊断中心、医院和研究实验室，并进一步细分为院内实验室和独立实验室、综合医院和专科移植中心以及研究机构，这些机构正在推动实验性检测的早期应用。这些细分结构共同突显了在自动化、数据整合和临床检验方面进行投资能够产生最大营运和临床影响的领域。

区域趋势和战略意义：影响美洲、欧洲、中东和非洲以及亚太地区诊断技术应用和普及的因素

区域趋势对诊断技术的可近性、监管预期和商业策略产生了深远影响，美洲、欧洲、中东和非洲地区以及亚太地区呈现出截然不同的模式。在美洲，大型学术移植中心和综合检测网路往往推动高解析度分子侦测的早期应用，而采购方式也越来越重视能够减轻营运负担的整合供应商服务解决方案。向东北方向的欧洲、中东和非洲地区发展，由于法规结构和报销体系的多样性，供应商需要投资于区域性证据产生和灵活的定价策略。此外，互通性和外部品质保证也日益受到重视。

在亚太地区，医院基础设施的快速投资和移植项目的扩张为集中式和分散式检查模式都创造了巨大的成长潜力。然而，区域供应链的差异和各地监管政策的不同要求企业采取适应性强的市场进入策略。总而言之，这些区域趋势凸显了在地化市场准入、区域性检验数据以及与领先的移植中心建立合作伙伴关係的重要性，以加速临床应用并确保服务的永续提供。

竞争格局和企业级策略结合平台创新、临床伙伴关係和服务模式，以推动市场采纳。

移植诊断生态系统中的主要企业透过平台广度、检测能力、监管专业知识以及降低临床实验室采用门槛的服务模式来脱颖而出。成熟的平台供应商强调整合检测、自动化和资料管理的解决方案，使医院和参考实验室能够简化检验和报告流程。同时，专业的分子诊断技术开发人员专注于高解析度HLA型检测、标靶定序panel和超灵敏排斥标记等细分领域检测，并经常与临床实验室合作进行共同开发和真实世界资料收集。

除了产品创新，成功的公司还会投资于供应链韧性、本地技术支援，并建立清晰的临床效用故事，以引起移植项目和支付方的共鸣。供应商与移植中心之间的策略联盟透过早期准入计划和合作研究加速产品应用，而合约实验室网路和诊断服务供应商透过提供可扩展的检测能力来扩大覆盖范围。最后，优先考虑互通资料解决方案和可操作报告格式的公司能够提高临床团队的接受度，因为这些功能可以直接支援更快的临床决策和更好的患者预后。

为产业领导者提供切实可行的建议，以协调创新、供应链韧性和临床参与，从而加速技术推广应用。

我们鼓励产业领导者优先考虑务实的、分阶段的方法，在临床创新和营运可靠性之间取得平衡，以确保移植项目能够持续采用这些技术。首先，将研发投资与具有高影响力的临床应用案例结合，优先开发已被证实能够改善分配决策、排斥反应检测和感染监测的检测方法，同时规划严格的真实世界检验。其次，透过多源策略和区域製造伙伴关係关係来强化供应链，最大限度地降低外部政策突变带来的风险，并确保关键工作流程所需试剂的持续供应。

同时，需要投资于无缝数据整合和报告标准，以减轻移植临床医生的认知负担，并实现多中心比较。销售团队应促进与主要移植中心合作产生证据，并设计灵活的商业模式，以适应医院的采购週期和实验室认证要求。最后，可以提供结合培训、技术支援和结果追踪的模组化服务，以促进快速实施和持续改进，从而将临床证据转化为长期专案应用。

该研究基于透明的调查方法，明确指出了资料来源、检验方法、分析框架以及支持其研究结果的局限性。

本研究整合了对同侪审查的临床文献、监管指南文件、技术白皮书和检验的实验室实践资源进行系统性回顾的结果，并辅以来自移植中心、诊断实验室和采购部门专家的定性意见。分析架构包括移植诊断工作流程的横断面流程图绘製、技术能力比较以及专注于供应链和政策差异的情境分析。研究结果透过跨多个资料来源的三角验证进行检验，以确保其一致性并识别临床意图与实验室实践之间的差距。

限制包括专有检测方法的已发布性能指标存在差异，以及各实验室报告规范的不一致。我们的调查方法旨在透过强调可重复的标准和透明的假设来减轻这些限制。在缺乏原始数据的情况下，我们咨询了专家，以阐明操作影响和实施障碍。这种方法提供了一种兼顾严谨性和实用性的综合方法，对参与诊断选择、实验室实施和临床专案设计的相关人员具有重要意义。

对优先趋势、策略要务和协作行动进行关键性综合分析，将诊断创新转化为临床成果

摘要，器官移植诊断领域正处于转折点，高解析度检测和改进的操作模式为改善临床疗效提供了清晰的路径——前提是相关人员能够解决与证据生成、供应永续性和工作流程整合相关的实际限制。虽然技术进步能够实现更精准的供受者配对和更早发现不利事件，但其应用取决于供应商、实验室和移植中心能否证明其临床效用、确保稳定的供应，并将检测结果整合到可操作的诊疗路径中。此外，区域和政策趋势要求针对检验、定价和分销采取符合当地监管和报销环境的客製化方法。

决策者在评估各种机会时，应重视多方合作的重要性——将临床科学家、实验室主任、采购负责人和行业合作伙伴聚集在一起，推动诊断解决方案的试点、检验和规模化，从而改善患者照护——使相关人员能够将技术潜力转化为可衡量的临床影响和永续的运营模式，以支持现在和未来的移植项目。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将供体来源的游离DNA检测纳入肾移植受者早期排斥反应检测的准确性
  • 引入多重免疫检测检测方法，用于预测肝臟移植受者的急性排斥反应并制定个人化的免疫抑制治疗方案
  • 开发人工智慧驱动的影像分析演算法，以识别移植血管疾病的早期征兆并量化移植血管灌注。
  • 快速照护现场基因表现谱分析技术在心臟移植病患免疫状态监测的应用
  • 利用常温机械灌註生物标记扩大肺移植中供体器官活力的评估

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 器官移植诊断市场（依检测类型划分）

  • 基因检测
    • DNA定序
    • SNP基因基因型鉴定
  • 组织相容性
    • 交叉配对试验
    • HLA型检测
  • 分子
    • 次世代定序
    • PCR
  • 血清学
    • ELISA
    • 流式细胞技术

9. 按器官类型分類的器官移植诊断市场

  • 心
  • 肾
    • 已故捐赠者
    • 活体捐赠者
  • 肝
    • 已故捐赠者
    • 活体捐赠者
  • 肺
  • 胰臟

第十章 依技术分類的器官移植诊断市场

  • ELISA
    • 竞争性ELISA
    • 夹心ELISA
  • 流式细胞技术
    • 细胞分选
    • 免疫表型分析
  • 微阵列
    • 表达式数组
    • SNP晶片
  • 次世代定序
    • 标靶定序
    • 全基因测序
  • PCR
    • 数位PCR
    • 即时PCR

第十一章 依应用分類的器官移植诊断市场

  • 移植后监测
    • 传染病筛检
    • 拒收监测
  • 移植前相容性测试
    • 横断面研究
    • HLA配对

第十二章 依最终使用者分類的器官移植诊断市场

  • 诊断中心
    • 医院检查室
    • 独立检验机构
  • 医院
    • 综合医院
    • 移植中心
  • 研究所

第十三章 各地区器官移植诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 器官移植诊断市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国器官移植诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Roche Holding AG
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • Danaher Corporation
    • bioMerieux SA
    • QIAGEN NV
    • PerkinElmer, Inc.
    • DiaSorin SpA
    • Bio-Rad Laboratories, Inc.
Product Code: MRR-5C6F41F5B031

The Organ Transplant Diagnostics Market is projected to grow by USD 8.08 billion at a CAGR of 7.69% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.46 billion
Estimated Year [2025] USD 4.80 billion
Forecast Year [2032] USD 8.08 billion
CAGR (%) 7.69%

Strategic overview of organ transplant diagnostics highlighting current clinical priorities and operational dynamics shaping adoption

Organ transplant diagnostics sit at the intersection of precision medicine, laboratory innovation, and complex clinical workflows, where timely and accurate testing determines graft outcomes and patient survival. Diagnostic modalities span genetic profiling, histocompatibility assessment, molecular surveillance, and serological interrogation, each contributing distinct clinical value from donor selection through long-term posttransplant monitoring. Recent years have seen the clinical community demand both higher resolution molecular data and operational simplicity to fit within tight clinical timelines, driving vendors and laboratories to re-evaluate platform interoperability and result turnaround strategies.

Consequently, clinical and commercial stakeholders must appreciate how testing pathways integrate with transplant program logistics, immunosuppression strategies, and infection surveillance protocols. When interpreted alongside clinical context, test outputs reduce immunologic risk, guide immunomodulation, and improve allocation decisions. As the sector evolves, decision-makers will need to balance novel high-resolution assays and analytics with practical constraints such as laboratory accreditation, reimbursement frameworks, and supply continuity. With these priorities in mind, this executive summary synthesizes the primary inflection points shaping diagnostics adoption, identifies segmentation-driven opportunities, and outlines pragmatic recommendations for leaders aiming to translate evidence into operational advantage.

Critical transformative shifts reshaping transplant diagnostics driven by technological innovation, regulatory focus, and clinical workflow realignment

The landscape of transplant diagnostics is undergoing transformative shifts driven by converging technological advances, regulatory recalibration, and evolving clinical practice patterns. Next-generation sequencing and high-sensitivity molecular assays have raised the bar for diagnostic resolution, enabling more precise donor-recipient matching and earlier detection of rejection or infection. At the same time, improvements in assay automation and digital reporting have reduced manual steps and enabled faster clinical decision cycles, prompting transplant teams to redesign workflows around timely laboratory inputs.

Simultaneously, payers and health systems are emphasizing value-based outcomes, pushing diagnostics suppliers to demonstrate clinical utility through real-world evidence and cost-offset analyses. Regulatory agencies have become more focused on assay standardization and interoperability, which encourages vendors to pursue harmonized protocols and external quality assessment participation. Moreover, supply chain resilience has emerged as a strategic priority, with stakeholders favoring diversified reagent sources and validated contingency plans. Together, these shifts create a market environment where technological differentiation must be matched by evidence generation, supply stability, and operational integration to win adoption across transplant centers and diagnostic laboratories.

Projected cumulative implications of changes in United States tariff policy on diagnostic supply chains, procurement strategies, and clinical access

Policy actions that alter tariff structures can materially affect the availability, cost base, and procurement strategies for diagnostic platforms and consumables, with significant implications for transplant programs that rely on specialized assays and international supply chains. When tariffs increase, laboratories and hospitals often respond by sourcing alternative suppliers, aggregating purchases through centralized procurement, or accelerating local validation of compatible reagents and instruments. Conversely, reductions or clarifications in tariff policy typically restore predictable procurement lead times and support investment in platform upgrades that were previously deferred due to cost uncertainty.

In practice, the cumulative impact on transplant diagnostics includes shifts in inventory management practices, a reassessment of supplier contracts to include tariff-related clauses, and renewed emphasis on regional manufacturing partnerships to insulate critical supply lines. Importantly, diagnostic decision-makers must also consider indirect effects: tariff-induced cost pressures can slow validation of new assays, compress margins for specialized testing providers, and influence decisions about onshoring versus continued international sourcing. To mitigate operational disruption, clinical laboratories and hospital systems should strengthen supply chain visibility, renegotiate terms to include service-level protections, and prioritize diverse vendor ecosystems that reduce exposure to single-source tariff shocks.

Granular segmentation insights connecting diagnostic modalities, organ-specific workflows, enabling technologies, clinical applications, and end-user capabilities

A nuanced segmentation approach reveals distinct demand drivers and operational imperatives across test types, organ indications, enabling technologies, applications, and end-user settings. Test type distinctions separate genetic assays that include DNA sequencing and SNP genotyping from histocompatibility workflows such as crossmatching and HLA typing, and further differentiate molecular methods like next-generation sequencing and PCR from serological techniques including ELISA and flow cytometry. These diagnostic modalities map directly to organ-specific requirements, where heart, kidney, liver, lung, and pancreas programs prioritize different sensitivity, throughput, and turnaround characteristics; kidney and liver programs further bifurcate based on deceased donor and living donor workflows, affecting pretransplant matching and posttransplant surveillance needs.

From a technology vantage, ELISA and flow cytometry remain foundational for many laboratories, while microarray platforms, targeted or whole genome sequencing, and advanced PCR variants support deeper immunogenetic profiling. Application-wise, pretransplant matching activities such as crossmatch testing and HLA matching demand rapid, high-specificity outputs to inform allocation, whereas posttransplant monitoring focuses on infection screening and rejection surveillance that require longitudinal sampling and reliable quantitation. End-user ecosystems span diagnostic centers, hospitals, and research laboratories, with sub-segmentation into hospital labs versus independent labs, general hospitals versus specialized transplant centers, and research entities that often drive early adoption of experimental assays. Taken together, this segmentation fabric highlights where investments in automation, data integration, and clinical validation will deliver the greatest operational and clinical return.

Region-specific dynamics and strategic implications across Americas, Europe Middle East & Africa, and Asia-Pacific influencing diagnostic deployment and uptake

Regional dynamics exert a profound influence on diagnostic availability, regulatory expectations, and commercial strategies, with distinct patterns emerging across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, large academic transplant centers and consolidated laboratory networks tend to drive early adoption of high-resolution molecular assays, while procurement approaches increasingly favor integrated vendor-service solutions that reduce operational burden. Transitioning northeast to Europe Middle East & Africa, regulatory frameworks and reimbursement heterogeneity require vendors to invest in localized evidence generation and flexible pricing strategies, and programs often place a premium on interoperability and external quality assurance.

Across Asia-Pacific, rapid investment in hospital infrastructure and expanding transplant programs create high growth potential for both centralized and decentralized testing models, yet regional supply chain considerations and local regulatory variations necessitate adaptive go-to-market approaches. Collectively, these regional patterns underscore the importance of tailored market engagement, region-specific validation data, and collaborative partnerships with leading transplant centers to accelerate clinical acceptance and ensure sustainable service delivery.

Competitive landscape and company-level strategies that combine platform innovation, clinical partnerships, and service models to drive adoption

Leading companies in the transplant diagnostics ecosystem differentiate through a combination of platform breadth, assay performance, regulatory expertise, and service models that reduce implementation friction for clinical laboratories. Established platform vendors emphasize integrated solutions that bundle assays, automation, and data management, enabling hospitals and reference laboratories to streamline validation and reporting. At the same time, specialist molecular innovators focus on niche assays such as high-resolution HLA typing, targeted sequencing panels, and ultra-sensitive rejection markers, often partnering with clinical laboratories for co-development and real-world evidence generation.

Beyond product innovation, successful players invest in supply chain resilience, local technical support, and clear clinical utility narratives that resonate with transplant programs and payers. Strategic partnerships between vendors and transplant centers accelerate adoption through early access programs and collaborative studies, while contract laboratory networks and diagnostic service providers expand reach by offering scalable testing capacity. Finally, companies that prioritize interoperable data solutions and actionable reporting formats create stickiness with clinical teams, as these capabilities directly support faster clinical decisions and better patient outcomes.

Actionable recommendations for industry leaders to synchronize innovation, supply resilience, and clinical engagement to accelerate adoption

Industry leaders should prioritize a pragmatic, phased approach that balances clinical innovation with operational reliability to secure sustained adoption across transplant programs. First, align R&D investments with high-impact clinical use cases, prioritizing assays that demonstrably improve allocation decisions, rejection detection, or infection surveillance while planning rigorous real-world validation. Next, fortify supply chains through multi-sourcing strategies and regional manufacturing partnerships to minimize exposure to external policy shocks and ensure ongoing reagent availability for critical workflows.

Concurrently, invest in seamless data integration and reporting standards that reduce cognitive load for transplant clinicians and support multi-center comparability. Commercial teams should pursue collaborative evidence generation with leading transplant centers and design flexible commercial models that accommodate hospital purchasing cycles and laboratory accreditation requirements. Finally, develop modular service offerings that combine training, technical support, and outcome-tracking to facilitate rapid implementation and continuous improvement, thereby converting clinical proof points into long-term programmatic adoption.

Transparent research methodology describing data sources, validation approaches, analytical frameworks, and limitations informing the insights

This research synthesizes insights from a structured review of peer-reviewed clinical literature, regulatory guidance documents, technical white papers, and validated laboratory practice resources, supplemented by qualitative inputs from subject matter experts across transplant centers, diagnostic laboratories, and procurement functions. Analytical frameworks included cross-sectional process mapping of transplant diagnostic workflows, technology capability comparisons, and scenario analysis focused on supply chain and policy perturbations. Findings were validated through triangulation across diverse data sources to ensure consistency and to identify points of practical divergence between clinical intent and laboratory operations.

Limitations include variability in publicly available performance metrics for proprietary assays and heterogeneity in reporting practices across centers, which the methodology seeks to mitigate by emphasizing reproducible decision criteria and transparent assumptions. Where primary data gaps remained, expert consultations helped contextualize likely operational impacts and adoption barriers. This approach yields an actionable synthesis that balances rigor with practical relevance for stakeholders involved in diagnostic selection, laboratory implementation, and clinical program design.

Conclusive synthesis of priority trends, strategic imperatives, and collaborative actions to translate diagnostic innovation into clinical outcomes

In sum, the organ transplant diagnostics domain is at an inflection point where higher-resolution assays and improved operational models offer clear paths to better clinical outcomes, provided stakeholders address practical constraints around evidence generation, supply resilience, and workflow integration. Technological advances enable more precise donor-recipient matching and earlier detection of adverse events, but adoption depends on the ability of vendors, laboratories, and transplant centers to demonstrate clinical utility, ensure consistent supply, and embed testing outputs into actionable care pathways. Moreover, regional and policy dynamics require tailored approaches to validation, pricing, and distribution that respect local regulatory and reimbursement landscapes.

As decision-makers evaluate opportunities, the emphasis should remain on multi-stakeholder collaboration: aligning clinical scientists, laboratory leaders, procurement officers, and industry partners to pilot, validate, and scale diagnostic solutions that improve patient care. By doing so, stakeholders can translate technological promise into measurable clinical impact and sustainable operational models that support transplant programs now and into the future.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of donor-derived cell-free DNA assays to enhance early rejection detection in kidney transplant recipients
  • 5.2. Adoption of multiplex immunoassay panels to predict acute rejection and tailor immunosuppressive regimens for liver transplant patients
  • 5.3. Development of AI-driven imaging algorithms for quantifying graft perfusion and identifying early signs of transplant vasculopathy
  • 5.4. Emergence of rapid point-of-care gene expression profiling to monitor immune status in heart transplant recipients
  • 5.5. Expansion of donor organ viability assessment using normothermic machine perfusion biomarkers in lung transplantation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Organ Transplant Diagnostics Market, by Test Type

  • 8.1. Genetic
    • 8.1.1. Dna Sequencing
    • 8.1.2. SnP Genotyping
  • 8.2. Histocompatibility
    • 8.2.1. Crossmatching
    • 8.2.2. Hla Typing
  • 8.3. Molecular
    • 8.3.1. Next Generation Sequencing
    • 8.3.2. Pcr
  • 8.4. Serological
    • 8.4.1. Elisa
    • 8.4.2. Flow Cytometry

9. Organ Transplant Diagnostics Market, by Organ Type

  • 9.1. Heart
  • 9.2. Kidney
    • 9.2.1. Deceased Donor
    • 9.2.2. Living Donor
  • 9.3. Liver
    • 9.3.1. Deceased Donor
    • 9.3.2. Living Donor
  • 9.4. Lung
  • 9.5. Pancreas

10. Organ Transplant Diagnostics Market, by Technology

  • 10.1. Elisa
    • 10.1.1. Competitive Elisa
    • 10.1.2. Sandwich Elisa
  • 10.2. Flow Cytometry
    • 10.2.1. Cell Sorting
    • 10.2.2. Immunophenotyping
  • 10.3. Microarray
    • 10.3.1. Expression Arrays
    • 10.3.2. SnP Arrays
  • 10.4. Next Generation Sequencing
    • 10.4.1. Targeted Sequencing
    • 10.4.2. Whole Genome Sequencing
  • 10.5. Pcr
    • 10.5.1. Digital Pcr
    • 10.5.2. Real Time Pcr

11. Organ Transplant Diagnostics Market, by Application

  • 11.1. Posttransplant Monitoring
    • 11.1.1. Infection Screening
    • 11.1.2. Rejection Monitoring
  • 11.2. Pretransplant Matching
    • 11.2.1. Crossmatch Testing
    • 11.2.2. Hla Matching

12. Organ Transplant Diagnostics Market, by End User

  • 12.1. Diagnostic Centers
    • 12.1.1. Hospital Labs
    • 12.1.2. Independent Labs
  • 12.2. Hospitals
    • 12.2.1. General Hospitals
    • 12.2.2. Transplant Centers
  • 12.3. Research Laboratories

13. Organ Transplant Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Organ Transplant Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Organ Transplant Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Roche Holding AG
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Thermo Fisher Scientific Inc.
    • 16.3.4. Siemens Healthineers AG
    • 16.3.5. Danaher Corporation
    • 16.3.6. bioMerieux SA
    • 16.3.7. QIAGEN N.V.
    • 16.3.8. PerkinElmer, Inc.
    • 16.3.9. DiaSorin S.p.A.
    • 16.3.10. Bio-Rad Laboratories, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ORGAN TRANSPLANT DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ORGAN TRANSPLANT DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ORGAN TRANSPLANT DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)